InMed Announces Expected Closing of Merger and Commencement of Trading on Nasdaq Under the Name "Mentari Therapeutics, Inc." and Ticker Symbol "MTRI"

Vancouver, British Columbia--(Newsfile Corp. - November 5, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) (now Mentari Therapeutics, Inc.) (the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced that, subject to the satisfaction or waiver of the remaining closing conditions under the agreement and plan of merger and reorganization dated May 19, 2026 (as amended, the "Merger Agreement"), among the Company, Mentari Therapeutics, Inc., a Delaware corporation ("Mentari"), Indigo Merger Sub Corp. and Indigo Merger Sub II, LLC, the Company's previously announced merger with Mentari (the "Merger") is expected to close on November 6, 2026.

On the closing date and prior to the completion of the Merger, the Company expects to redomesticate from British Columbia, Canada to the State of Nevada. Effective at the commencement of trading on November 9, 2026, the Company's common stock is expected to begin trading on The Nasdaq Capital Market ("Nasdaq") under the name "Mentari Therapeutics, Inc." and the new symbol "MTRI", with a new CUSIP number of 587157108 and a new ISIN number of US5871571080.